CTOs on the Move

Soredex

www.soredex.com

 
Soredex is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.soredex.com
  • 1245 W Canal St
    Milwaukee, WI USA 53233
  • Phone: 414.747.1030

Executives

Name Title Contact Details

Similar Companies

Pss Imaging Inc

Pss Imaging Inc is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lourdes Hospital

Lourdes has as many faces as there are people in the community it serves. With its spiritual Catholic faith, Lourdes Hospital has provided compassionate care to those in need since 1925. In Binghamton, NY, our health system includes an Ambulatory Surgery Center, Home Care and Hospice services, and a Regional Cancer Center. Reaching beyond these boundaries, Lourdes has established a network of primary care physicians at convenient sites throughout the region. Our Mission In Motion program, provides women`s health services with a mobile medical van, making health care accessible to rural populations.

Cope Community Services

Cope Community Services is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

De Kroyft-Metz

De Kroyft-Metz is a Peoria, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.